Radiopharmaceutical specialist Lantheus Holdings is currently weighing a potential sale of the company after receiving a strategic takeover bid from private equity-backed Curium Pharma, Bloomberg News reported on Friday. The prospective transaction values the clinical imaging firm at approximately $7 billion. Discussions between the two medical entities are actively ongoing and a definitive agreement could materialize within weeks, though market observers note that no finalized decision has been achieved and the dialogue may not necessarily culminate in a formal combination. Following the publication, corporate shares of Lantheus, which commands a baseline market capitalization of $6.15 billion, slid by nearly 2% during extended trading hours.
The operational baseline and regulatory timeline defining Lantheus’ current fiscal year include several key metrics:
-
Financial Performance: Earlier this month, Lantheus delivered first-quarter adjusted core earnings that surpassed consensus analyst estimates, driven primarily by robust clinical demand for its proprietary oncological diagnostic imaging agents.
-
Corporate Guidance: Interim executive leadership has framed 2026 as a critical window centered on commercial execution and securing pivotal regulatory milestones to accelerate commercial scaling throughout 2027. However, the enterprise maintained its static full-year financial outlook, with investment analysts noting that an upward revision remains pending until a permanent Chief Executive Officer is formally installed.
-
Regulatory Review Extension: In March, the U.S. Food and Drug Administration (FDA) extended its regulatory review window for Lantheus’ diagnostic imaging kit, LNTH-2501, by an additional three months. The programmatic delay was instituted to allow investigators more time to thoroughly review manufacturing-related technical files, pushing the revised decision deadline to June 29.
-
Capacity Expansion Milestones: Separately in March, the federal health regulator granted marketing clearance for an updated formulation of Pylarify, the company’s frontline prostate cancer imaging agent. The pharmaceutical optimization is engineered to rapidly scale up aggregate manufacturing volume and expand clinical scanning availability across healthcare networks.
Regarding the bidding entity, Curium was valued at an identical $7 billion threshold last year when its parent asset manager, CapVest Partners, structured a specialized continuation vehicle to back the nuclear medicine manufacturer. At present, Lantheus has declined to comment on the transaction parameters, while Curium did not immediately issue a formal response to press inquiries regarding the status of the corporate talks.